Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors.

Advanced drug delivery reviews - 1 Sept 2025

Barrambana Sara, Zamorano-Domínguez Elena, Liaki Vasiliki, Guerra Carmen

Abstract excerpt

Pancreatic cancer is one of the most lethal types of cancer, known for a poor prognosis. Currently, the standard of care for unresectable tumors consists of combinations of cytotoxic chemotherapy. Thus far, targeted therapies against specific oncogenic pathways have not been approved for clinical use. Most cases of pancreatic cancer are sporadic/non-hereditary Pancreatic Ductal Adenocarcinomas (PDACs) and are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to KRAS gene

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 40645340
DOI: 10.1016/j.addr.2025.115652

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors.PMID 40645340Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

Critical role of oncogenic KRAS in pancreatic cancer (Review).Semantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).Semantic proximity Read ↗

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer: new drugs on the horizon.Semantic proximity Read ↗

Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.